If you find this podcast useful please give it a rating and review on iTunes by clicking here
Do you want to get instant company alerts to the front screen of your smartphone? Download the Vox Markets app here: www.VoxMarkets.co.uk/app
On today's Vox Markets Podcast: Shield Therapeutics, Xtract Resources and Alan Green
Carl Sterritt, CEO and Founder of Shield Therapeutics (STX) explains the significance of the lastest positive results received on its lead product, Feraccru®.
Shield is a de-risked, commercial stage, pharmaceutical company delivering innovative specialty pharmaceuticals to address patients' unmet medical needs. The Company's clear purpose is to help its patients become people again, by enabling them to enjoy the things that make the difference in their everyday lives. The Group has a marketed product, Feraccru®, for the treatment of iron deficiency in adults which has exclusive IP rights until the mid-2030s. Feraccru® is commercialised in the European Union by Norgine BV and the US Food and Drug Administration (FDA) is currently considering a New Drug Application (NDA), with a PDUFA (Prescription Drug User Fee Act) date of 27th July 2019.
Colin Bird, Executive Chairman of Xtract Resources (XTR) talks about the option agreement they've entered into for the copper-gold Eureka project in Zambia.
Xtract Resources (AIM: XTR) is a resource, development and mining company whose focus is and will be to acquire brown field resource projects with a view to release value for its shareholders. The projects targeted will be in regions where mining and infrastructure is prevalent and the mining regulations transparent. Their current operations are the Manica Gold and Alluvials projects in Mozambique. (Interview starts at 6 minutes 22 seconds)
Alan Green CEO of Brand Communications talks about:
Cadence (KDNC)
AudioBoom (BOOM)
Europa Metals (EUZ)
(Interview starts at 16 minutes 28 seconds)